Biogen Inc.: The Game-Changing Subcutaneous LEQEMBI Might Just Be Its Single-Biggest Future Growth Catalyst! 

Biogen Inc. provided a mixed set of results in its first quarter of 2025, revealing both opportunities for its growing portfolio and challenges with its traditional business lines. Starting with the positives, the company has made significant strides with its newer products, contrasting its historically dominant but declining multiple sclerosis (MS) portfolio. The newer products, including rare disease drugs like ZURZUVAE, LEQEMBI, and VUMERITY, now account for approximately 45% of Biogen’s product revenue. This marks a strategic pivot to build a diverse revenue base with these drugs showing strong growth potential globally.